Journal of Multidisciplinary Healthcare (Dec 2022)
Patient Experience Evaluation of the CMO-Based Pharmaceutical Care Model vs Usual Care in People Living with HIV
Abstract
Ramón Morillo-Verdugo,1 Alicia Lazaro-Lopez,2 Elena Alonso-Grandes,3 Maria Teresa Martin-Conde,4 Pilar Diaz-Ruiz,5 Emilio Molina-Cuadrado,6 María José Huertas-Fernandez,7 Herminia Navarro-Aznares,8 Vera Areas Del Aguila,9 Mercedes Gimeno-Gracia,10 Luis Margusino-Framiñán,11 Jose Manuel Martínez-Sesmero12 1Pharmacy Hospital Service, Hospital Valme, Área de Gestión Sanitaria Sur de Sevilla, Sevilla, Spain; 2Pharmacy Hospital Service, Hospital Universitario de Guadalajara, Guadalajara, Spain; 3Pharmacy Hospital Service, Hospital del Tajo, Madrid, Spain; 4Pharmacy Hospital Service, Hospital Clinic i Provincia, Barcelona, Spain; 5Pharmacy Hospital Service, Hospital Virgen de la Candelaria, Tenerife, Spain; 6Pharmacy Hospital Service, Hospital de Torrecárdenas, Almería, Spain; 7Pharmacy Hospital Service, Hospital Puerta del Mar, Cádiz, Spain; 8Pharmacy Hospital Service, Hospital Miguel Servet, Zaragoza, Spain; 9Pharmacy Hospital Service, Hospital de Ciudad Real, Ciudad Real, Spain; 10Pharmacy Hospital Service, Hospital Lozano Blesa, Zaragoza, Spain; 11Pharmacy Hospital Service, Complejo Hospitalario A Coruña, A Coruña, Spain; 12Pharmacy Hospital Service, Hospital Clínico San Carlos, Madrid, SpainCorrespondence: Alicia Lazaro-Lopez, Hospital Universitario de Guadalajara, C/Donante de Sangre s/n CP: 19002 (Castilla-La Mancha, Spain), Guadalajara, Spain, Tel +34 626915820, Email [email protected]: To compare patient experience in a real-life population of people living with HIV (PLWH) who received pharmaceutical care (PC) based on the Capacity-Motivation-Opportunity (CMO) model versus the traditional model.Methods: Prospective cohort study in PLWH receiving either CMO-based PC or traditional PC in Spain between October 2019 and June 2021 (24 weeks), performed by the pharmacy department of 14 Spanish hospitals. Participants were adult patients with a clinical diagnosis of HIV treated with antiretrovirals who had been monitored in the participating hospital pharmacies for > 1 year. Patient experience (IEXPAC questionnaire), clinical outcomes (cholesterol, triglycerides, HDL, glycated haemoglobin, and blood pressure), adherence to treatment, virologic control and patient satisfaction were determined.Results: Patient experience in the CMO group at week 24 was significantly better (7.6 vs 6.9) than in the traditional group, with a higher mean improvement. Adherence was better in the CMO group, particularly with regard to concomitant medications (53.2% to 91.7%, p< 0.001); no changes were observed in the traditional group. Patient satisfaction improved in the CMO group vs the traditional group (48 vs 44, p< 0.001).Conclusion: To our knowledge, this is the first study to compare CMO vs traditional methodology. The CMO model showed an overall improvement in real-life patient experience, satisfaction, and adherence to treatment compared to the traditional methodology.Keywords: pharmaceutical care, HIV/AIDS, medication adherence, patient satisfaction, outcome assessment